ARS Pharmaceuticals, Inc. SPRY Return on equity

Return on equity at other companies

Amneal Pharmaceuticals, Inc.AMRX

-52.8%-12.7pp

ViatrisVTRS

-2.8%-1.3pp

Neuropace, Inc.NPCE

-111.4%-13.1pp

Eton Pharmaceuticals, Inc.ETON

-34.2%+0.9pp

Talphera, Inc.TLPH

-118.4%+15.4pp

FAQ

What is ARS Pharmaceuticals, Inc.'s return on equity?

ARS Pharmaceuticals, Inc. (SPRY) reported return on equity of -136.4% in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s return on equity changed year-over-year?

ARS Pharmaceuticals, Inc.'s return on equity decreased by 1873.4% year-over-year, from -6.9% to -136.4%.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s return on equity?

Over 2 years (2023 to 2025), ARS Pharmaceuticals, Inc.'s return on equity has grown at a 106.8% compound annual growth rate (CAGR), from -21.6% to -92.3%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.